Title:COVID-19 Research, Public Health and Biomedical Basis
Volume: 19
Issue: 4
Author(s): Da-Yong Lu*Ting-Ren Lu
Affiliation:
- School of Life Sciences, Shanghai University, Shanghai, 200444, P.R. China
Keywords:
COVID-19, drug development, viral prevention, viral transmission, viral vaccines, socioeconomic burden.
Abstract:
The coronavirus outbreak (COVID-19, SARS-CoV-2) greatly impacts the world. Despite
great biomedical efforts, approximately 30-50% global population was at least once infected with
COVID. Human life expectancy is reduced by COVID-19 epidemics worldwide.
It is indispensable to prevent and treat COVID-19 as effectively as possible. In order to well prevent
and treat the coronavirus infection, clinical diagnostic or therapeutic paradigms should be updated.
Since the outside condition of COVID-19 prevention is imbalanced among regions and countries,
global prevention and treatment action should be aimed.
Despite global vaccination for COVID, a significant proportion of humans still constantly exposes and
infected with viruses. Advanced viral biological knowledge and vaccine techniques can alleviate viral
spread and promote therapeutics. Universal and specific preventive and treatment paradigms should be
designed, integrated, and introduced.
The origin and hidden nature of COVID-19 biology and pathogenesis are broadly understood now. Viral
vaccines, pathogenesis, diagnosis, treatment, and personalized medicine are progressing rapidly.
Many viral vaccines and personalized medicine should be especially emphasized.
To speed up global efforts against COVID-19, new knowledge and breakthroughs of viral transmissibility,
vaccine technique innovation, diagnostic widening, and therapeutic variability worldwide are
discussed. Different strategic platforms and landscapes can reach different outcomes. By facilitating
global machinery against different variants of COVID, viral-induced socioeconomic burden and imbalance
could be reduced.
